Kaleido Biosciences Inc. is a clinical-stage healthcare company. It focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company's product candidates are Microbiome Metabolic Therapies(TM), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ's existing microbes. Kaleido Biosciences Inc. is based in Lexington, Massachusetts.